|
KMID : 0624620210540010070
|
|
BMB Reports
2021 Volume.54 No. 1 p.70 ~ p.88
|
|
|
Update of early phase clinical trials in cancer immunotherapy
|
|
Lee Dae-Ho
|
|
|
Abstract
|
|
|
|
Immunotherapy has revolutionized the landscape of cancer treatment and become a standard pillar of the treatment. The two main drivers, immune checkpoint inhibitors and chimeric antigen receptor T cells, contributed to this unprecedented success. However, despite the striking clinical improvements, most patients still suffer from disease progression because of the evolution of primary or acquired resistance. This mini-review summarizes new treatment options including novel targets and interesting combinational approaches to increase our understanding of the mechanisms of the action of and resistance to immunotherapy, to expand our knowledge of advances in biomarker and therapeutics development, and to help to find the most appropriate option or a way of overcoming the resistance for cancer patients.
|
|
|
KEYWORD
|
|
|
Cancer immunotherapy, Clinical trials, Novel biomarkers, Novel therapies, Preclinical study
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
  
|
|